Liberum Capital reaffirmed their buy rating on shares of PureTech Health (LON:PRTC) in a research report released on Thursday morning, ThisIsMoney.Co.Uk reports.
PRTC has been the subject of a number of other reports. Peel Hunt reaffirmed a buy rating on shares of Costain Group in a research report on Friday, June 28th. Jefferies Financial Group lifted their price objective on shares of PureTech Health from GBX 280 ($3.66) to GBX 340 ($4.44) and gave the stock a buy rating in a research report on Friday, July 5th.
PRTC stock opened at GBX 240 ($3.14) on Thursday. The company has a debt-to-equity ratio of 7.19, a quick ratio of 0.95 and a current ratio of 0.98. The stock’s fifty day moving average is GBX 223.52. PureTech Health has a one year low of GBX 135 ($1.76) and a one year high of GBX 239 ($3.12). The company has a market capitalization of $677.99 million and a PE ratio of -15.00.
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.